

For more than 30 years, we've been delivering vital statistical strategy that helps mitigate risks during product development. Phase I- IV, our expertise has you covered.

|



**MCDUGALL
SCIENTIFIC**
INSIGHTS YOU CAN TRUST



John
Amrhein

VP of McDougall Scientific, former Senior Statistician at SAS Institute (Canada) where he taught statistics and programming, and consulted with clients in health care, pharmaceuticals, finance, and government.

John was a Mathematical Statistician with the U.S. Department of Agriculture where he designed probability-based surveys of the U.S. agribusiness sector.

John is Chair of SAS Global Forum 2017.

WHAT IF THERE WAS A WAY TO DESIGN/ LAUNCH/ RUN/ ADVANCE
YOUR CLINICAL TRIAL TO WITHSTAND CHANGES, ENSURE
COMPLIANCE AND IMPROVE YOUR TIME TO MARKET THEREBY
SAVING YOU MONEY?



The Statistician's Toolbox

Operationally
Seamless Designs

Simulations

Adaptive Designs
randomization

Inferentially
Seamless Designs

Interim Analyses

Design Features

Variety of Analysis Models

Bayesian Inferential Methods

A laptop is shown from a low angle, displaying a dashboard with various data visualizations. The dashboard includes a sidebar with a user profile for 'Anthony Mulya', a top row of six key metrics (Total Users, Average Time, Total Sales, Total Revenue, Total Customers, Total Lifetime), and a central area with a large area chart and several smaller charts below it. The text 'Toolbox in action: a case study' is overlaid in white on the dashboard. Below it, a paragraph in light blue text describes a biotech case study.

Toolbox in action: a case study

A BIOTECH IS DEVELOPING A TREATMENT FOR SEXUAL DYSFUNCTION
A phase 2 study provided many learnings, including a substantial placebo effect and very high patient-to-patient variability, possibly masking an efficacy signal, among others.

Toolbox in action: a 2nd case study

A BIOTECH IS DEVELOPING A TREATMENT FOR CANCER

The target population includes only those patients for whom the standard of care has failed; 25% of all treated. The target cancer has two tumor types; one can be resected before treatment, the other cannot.



The Takeaway: Plan.

Adaptive design can be nimble, the smarter your plan, the better your results.

Speak with me: 416.673.9474

Write: jamrhein@mcdougallscientific.com

Read the complete whitepaper here: <http://www.mcdougallscientific.com/take-the-pain-out-of-clinical-trials/>